Tugba Akin Telli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/734690/publications.pdf

Version: 2024-02-01

1684188 1281871 27 144 5 11 citations g-index h-index papers 27 27 27 251 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study. Journal of Cancer Research and Clinical Oncology, 2023, 149, 865-875.	2.5	1
2	Predictive value of 18F-FDG PET/CT indices on extensive residual cancer burden in breast cancer patients treated with neoadjuvant chemotherapy. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2022, 41, 171-178.	0.2	1
3	Impact of Skeletal Muscle Measurements by Chest Computed Tomography on Survival and Postoperative Complications in Patients with Soft Tissue Sarcoma. Nutrition and Cancer, 2022, , 1-9.	2.0	2
4	Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience. Journal of Oncology Pharmacy Practice, 2021, 27, 329-339.	0.9	1
5	A rare case of gastric cancer with bilateral breast metastasis during pregnancy. Journal of Oncology Pharmacy Practice, 2021, 27, 220-226.	0.9	6
6	Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature. Current Problems in Cancer, 2021, 45, 100668.	2.0	7
7	A rare case of primary rectal choriocarcinoma and review of the literature. Journal of Oncology Pharmacy Practice, 2020, 26, 989-994.	0.9	9
8	How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature. Journal of Oncology Pharmacy Practice, 2020, 26, 1011-1018.	0.9	14
9	PD-1 and PD-L1 inhibitors in oesophago-gastric cancers. Cancer Letters, 2020, 469, 142-150.	7.2	34
10	Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib. Journal of Oncology Pharmacy Practice, 2020, 26, 1147-1155.	0.9	6
11	Differences in PET/CT standardized uptake values involvement and survival compared to histologic subtypes of lung adenocarcinoma. Tumori, 2020, 107, 030089162095047.	1.1	3
12	Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment. Clinical Neurology and Neurosurgery, 2020, 196, 105976.	1.4	0
13	QT interval prolongation related to afatinib treatment in a patient with metastatic non–small-cell lung cancer. Current Problems in Cancer, 2020, 44, 100594.	2.0	6
14	Response Assessment With Molecular Characterization of Circulating Tumor Cells and Plasma MicroRNA Profiling in Patients With Locally Advanced Breast Cancer During Neoadjuvant Chemotherapy. Clinical Breast Cancer, 2020, 20, 332-343.e3.	2.4	5
15	VEGF-VEGFR pathway seems to be the best target in hepatic epithelioid hemangioendothelioma: A case series with review of the literature. Current Problems in Cancer, 2020, 44, 100568.	2.0	6
16	Gray areas and evidence gaps in the management of rectal cancer as revealed by the comparison of recommendations from national and international clinical guidelines Journal of Clinical Oncology, 2020, 38, 74-74.	1.6	0
17	Clinicopathologic Features of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) s: A Single-Center Experience. Balkan Medical Journal, 2020, 37, 281-286.	0.8	2
18	Comparison of two different carboplatin and weekly paclitaxel schedule in elderly advanced non-small cell lung cancer patients. Cancer Chemotherapy and Pharmacology, 2019, 83, 1137-1145.	2.3	1

#	Article	IF	CITATIONS
19	A correlation study of fluorouracil pharmacodynamics with clinical efficacy and toxicity. Tumori, 2018, 104, 157-164.	1.1	8
20	Chordoma: a case series and review of the literature. Journal of Medical Case Reports, 2018, 12, 239.	0.8	23
21	Clinicopathologic features of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): A single-center experience Journal of Clinical Oncology, 2018, 36, e16168-e16168.	1.6	O
22	Prognostic factors in early stage lung cancer patients: Retrospective single center data Journal of Clinical Oncology, 2018, 36, e20500-e20500.	1.6	0
23	The effect of thyroid autoantibody positivity on the functions of internal ear. European Archives of Oto-Rhino-Laryngology, 2017, 274, 3853-3858.	1.6	2
24	Eliminating fluorouracil toxicity without sacrificing efficacy in colorectal cancer. Annals of Oncology, 2017, 28, iii99-iii100.	1.2	0
25	Does metabolic syndrome or its components associate with prostate cancer when diagnosed on biopsy?. Therapeutic Advances in Medical Oncology, 2015, 7, 63-67.	3.2	6
26	Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy. Future Oncology, 0, , .	2.4	0
27	Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncology, 0, , .	2.4	1